US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment

The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B drug Hibsago, allowing patients ​with the liver infection a way to keep the virus under ‌control after stopping treatment...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。